BMY watch $46.xx: Double Golden zone that could mark the BottomBMY has been dropping along with pharma sector.
Bulls regained Double Golden zone but not safe yet.
Looking for a Break-and-Retest to mark the bottom.
Key facts today
17,965.10
0.01 BRL
−48.24 B BRL
260.38 B BRL
About Bristol-Myers Squibb Company
Sector
Industry
CEO
Christopher S. Boerner
Website
Headquarters
Princeton
Founded
1933
ISIN
BRBMYBBDR000
FIGI
BBG0025NPDT2
Bristol Myers Squibb Co. engages in the discovery, development, licensing, manufacture, marketing, distribution, and sale of biopharmaceutical products. It offers small molecules, products produced from biological processes called biologics, and chimeric antigen receptor (CAR-T) cell therapies. The company was founded in August 1933 and is headquartered in Princeton, NJ.
−105%
−70%
−35%
0%
35%
Q1 '24
Q2 '24
Q3 '24
Q4 '24
Q1 '25
−80.00 B
−40.00 B
0.00
40.00 B
80.00 B
Revenue
Net income
Net margin %
Revenue
COGS
Gross profit
Op expenses
Op income
Non-Op income/ expenses
Taxes & Other
Net income
0.00
17.00 B
34.00 B
51.00 B
68.00 B
Revenue
COGS
Gross profit
Expenses & adjustments
Net income
0.00
17.00 B
34.00 B
51.00 B
68.00 B
No news here
Looks like there's nothing to report right now
$BMYLooks like price is near a support range dating back between November and February of 2024. If you look at the "throw up" emoji, there was a nice flat down drop in price and since then, it seems like we are at the brink of possibly starting to gas out a bit for some potential relief. They just came
Bristol will fall an extra 10%NYSE:BMY has reported somewhat disappointing results for 2025, and the investors' disappointment is evident in the breakdown of the double top that had formed.
This suggests a likely drop of about 10% in the stock price, although it doesn't affect the long term. The weaker sales in generic dr
BMY: Technical and Fundamental AnalysisBMY: Technical and Fundamental Analysis
Two recent developments initiated a bearish movement in BMY last week:
News_1: Bristol-Myers Squibb's Melanoma Treatment Fails to Meet Primary Endpoint in Phase 3 Adjuvant Trial
Bristol-Myers Squibb said its Phase 3 trial evaluating opdualag for the adjuv
Speculative Madness: The Market’s Bubble Stocks Some stocks areSpeculative Madness: The Market’s Bubble Stocks
Some stocks aren't just overvalued—they're in full speculative bubble mode. Fundamentals? Irrelevant. When euphoria takes over, rationality disappears.
Here’s my list of bubble stocks that scream unsustainable pricing:
SBUX, T, PLTR, BMY, PYPL, NFLX
Bristol-Myers Squibb (BMY): A Strong Player in BiopharmaBristol-Myers Squibb Company (BMY) is a global biopharmaceutical leader focused on developing innovative medicines to address serious diseases. The company specializes in treatments for cancer, cardiovascular conditions, and immune disorders. With a portfolio that includes well-known drugs like Opdi
$BMY #BMY happens to be my better July was slow as in hell , but I stick with trading NYSE:BMY for the whole month , #WEBBY's #RSI was a big help to check on funds liquidity infusion , trim from dividend's collected from #oilandgas
Freedom was in trade and secured by capital available 2x and second 3x $ i.e. 1/2 and 3/4 on each
BMY Swing TradeBristol-Myers Squibb Co (BMY)
BMY has been on a downtrend since December 2022 but since its recent Dividend payout followed by good earnings, it seems like a reversal of trend is in the making.
Following a month-long consolidation period, a bullish candlestick formation at today's close could indi
See all ideas
Summarizing what the indicators are suggesting.
Oscillators
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Oscillators
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Summary
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Summary
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Summary
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Moving Averages
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Moving Averages
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Displays a symbol's price movements over previous years to identify recurring trends.
US110122DS4
BRIST.MYERS 20/50Yield to maturity
7.57%
Maturity date
Nov 13, 2050
US110122DX3
BRIST.MYERS 22/62Yield to maturity
6.84%
Maturity date
Mar 15, 2062
US110122DW5
BRIST.MYERS 22/52Yield to maturity
6.81%
Maturity date
Mar 15, 2052
US110122DR6
BRIST.MYERS 20/40Yield to maturity
6.78%
Maturity date
Nov 13, 2040
BMY3883364
Bristol-Myers Squibb Company 3.25% 01-AUG-2042Yield to maturity
6.63%
Maturity date
Aug 1, 2042
BMY5009254
Bristol-Myers Squibb Company 4.25% 26-OCT-2049Yield to maturity
6.50%
Maturity date
Oct 26, 2049
US110122DV7
BRIST.MYERS 22/42Yield to maturity
6.42%
Maturity date
Mar 15, 2042
See all BMYB34 bonds
Curated watchlists where BMYB34 is featured.
